Author Archives: admin


Unproven stem cell products are being peddled as COVID-19 ‘therapies,’ U of M researcher reports – MinnPost

Coronavirus health scams are rampant, with businesses taking advantage of peoples fears to sell all sorts of unproven products for the prevention and treatment of COVID-19. Some of these snake oil cures are innocuous, such as elderberry juice, but others can be harmful, such as colloidal silver.

Among the products with considerable potential for harm are unproven stem cell therapies. Unfortunately, the emergence of this particular line of sham COVID-19 treatments isnt all that surprising. For more than a decade, businesses have been aggressively pitching unsubstantiated and unlicensed stem cell products to vulnerable and often desperate individuals with illnesses or injuries for which no known treatment exists, such as Alzheimers disease, amyotrophic lateral sclerosis (ALS), chronic obstructive pulmonary disease (COPD) and spinal cord injuries. The results have sometimes been deadly.

There are some medical conditions for which stem cell therapies have been shown to be safe and effective, but they are few in number mostly cancer and several blood and immune disorders.

Leigh Turner, a bioethicist at the University of Minnesota, has been investigating the direct-to-consumer marketing of spurious stem cell therapies and related exosome products in the United States for nearly a decade. In an article published recently in the journal Cell Stem Cell, Leigh describes the latest twist in this cynical saga: how some stem cell businesses are seizing the [COVID-19] pandemic as an opportunity to profit from hope and desperation.

MinnPost spoke with Turner late last week about what he found when researching that paper. The following is an edited transcript of the interview.

MinnPost: Companies seem to be using the same kind of marketing strategies to sell unproven stem cell therapies for COVID-19 as they have for other medical conditions.

Leigh Turner: Yes. These are opportunistic businesses. They look for marketplace opportunities, ways to generate e-revenue streams. And the COVID-19 pandemic is another business opportunity. Its not like theyve pivoted away from what they did in the past. If they were marketing stem cell treatments for Parkinsons disease, or ALS or spinal injuries, they havent stopped doing that. Theyve just added that theyve now got a stem cell treatment or an exosome therapy to treat or prevent COVID-19.

MP: They seem to be marketing their products primary as immune system boosters.

Leigh Turner

MP: At least one company is telling people that they should bank their stem cells to use as a treament if they get infected with the coronavirus.

LT: There are several business models at play right now. One is, come on in and get your stem cell immune booster to reduce your chances of getting COVID-19. They may also claim it will reduce your symptoms should you get it. Another marketing pitch is a bit more cautious. It says that if you come in now when youre in good health, they will bank your cells. Youll pay for the initial extraction of cells and also monthly or yearly for banking. The company then claims that should you fall ill with COVID-19 down the road, youll have those healthy cells available for you to use. Of course, they dont offer a lot of detail about how the cells would actually help you. You just supposed to take it for granted that they will.

MP: Theres no evidence of that.

LT: No. Its all just pseudoscience. But there is a meaningful hypothesis behind it. Thats how these businesses operate by fusing science with pseudoscience, credible research with junk claims.

MP: What is that hypothesis?

LT: There are companies and academic institutions right now that are interested in testing stem cell products, but not as immune boosters, not to prevent COVID-19 and not to eliminate the virus if someone gets infected. The studies right now are focusing on a very particular population of people with COVID-19 those who are typically in ICUs, suffering from acute respiratory distress syndrome. The hypothesis is that if certain types of stem cell products are administered to those people, we may be able to reduce inflammation in the lungs and help shorten the illness. But its a hypothesis.

MP: A good one?

LT: Its not an outrageous hypothesis. If you look at the existing literature, there have been studies done in the past that used stem cells for lung and respiratory disease. So far, those studies suggest that if you use clinical-grade stem cells and if you do it in a very rigorous way the safety profile is pretty good. But none of those studies has established extensive evidence of efficacy yet. Ideally, what you want is carefully designed, carefully conducted clinical trials testing that hypothesis and generating that evidence. These businesses the ones marketing stem cell therapies directly to individuals are not part of that scientific world.

MP: How do those businesses pull their customers in? How do they find them?

LT: They are typically big on social media. Im talking generally here, but they have Twitter accounts. They have YouTube channels. They have a Facebook page. Theyre not just putting up a website and hoping that somebody walks in the door. They hire social media marketing companies. They use marketing firms. They have pretty sophisticated marketing strategies that are tailored to particular demographics. It may be that they are targeting an elderly population, for example, because if youre interested in reaching people with COPD, youre not going to be trying to find 18-year-olds. Some businesses here in Minneapolis and elsewhere will have what they describe as educational seminars, which are basically infomercials. They are marketing events. They will try to get people to come to a convention center, a hotel [conference] room or a restaurant. Everything is free, but what theyll do is use hard-sell sales tactics to get people to commit, to write a check. Often theyll tell people that if they sign on today, theyll knock $2,000 or so off the price. But, of course, theyre not holding these events right now. They cant have these public gatherings.

MP: So, how are they selling people these products now, during the pandemic?

LT: More of it is happening online. One company, for example, uses a graduated pricing model. If its one person, its one price point. If its you and a family member, you both get a break on the procedure. And if its you and two additional family members, the price goes down even more. They use these things to try to get people to come in the door. One company in California has adapted to the pandemic in a different way. They have a do-it-yourself model. You dont have to even come into the clinic. You can buy their kit, and they ship it to your home. You then do the procedure at your dining room table.

MP: These stem cell products and treatments are quite expensive.

LT: Yes, some of the businesses Ive look at charge tens of thousands of dollars, although thats not necessarily for treating COVID-19. For COVID-19, it appears to be in the thousands-of-dollars category. In some cases, we dont know. The businesses can be pretty cagey. In some cases, they try to size up the customer and figure out how much they can extract from that person.

MP: Government agencies are cracking down on some of these stem cell businesses.

LT: The FDA (Food and Drug Administration), FTC (Federal Trade Commission) and Department of Justice have said that theyre going to be aggressive with dealing with these scams. And they have. Some businesses have already received letters from the regulators. That may be having a deterrent effect during the pandemic. Some businesses may want to jump in, but are afraid to do so. They may be waiting to see what happens before they take the chance.

MP: But the regulatory agencies are obviously not finding all of the businesses marketing unproven COVID-19 therapies.

LT: There is a lot of marketing fraud. And sometimes its quite challenging to figure out whats going on. Some of the clinics that I looked at didnt say, Were offering an immune booster for COVID-19. It was more just chatter. Clinics would put up a seven-minute video from one of their doctors about COVID-19 and emerging stem-cell research coming out of China, saying it was really encouraging. Then they would say, If you have any questions about stem cells and COVID-19, give us a call. So, whats the takeaway when a business does that? Does that mean they are selling stem cell treatments for COVID-19? Or are they just trying to get people to call? Its hard to know whats happening. If I had to guess, I say its a workaround. The businesses dont want to put it on their website, because thats too easy for someone from the FTC or the FDA to find. If they just put up a video, they can say theyre not marketing anything, that it was just meant to be educational.

MP: These businesses seem to rely on anecdotal cases or really small studies from China to support their claims.

LT: They use China in a couple of different ways. There was a case report, for example, that was published as a preprint. It wasnt published by a journal. It hasnt gone through peer review. It was just a preprint that someone put online. Its the case of a single individual with COVID-19 who received stem cells. Thats been written up in a very hyperbolic way, when really, its just a case report. Its one person. Some people get COVID-19 and recover anyway. You cant draw any conclusions from it about stem cells being efficacious, but its been written up that way. There was another study, very preliminary research, in which mesenchymal stem cells were administered to seven individuals with COVID-19 with various degrees of severity. A placebo was given to three individuals. The article doesnt provide the source of the stem cells. Nor does it provide much insight about the individuals who were given placebos, although they appear to be about 10 years older than [those receiving the stem cells]. It raises some interesting questions. It provides a basis for further research. But, unfortunately, some of the news media reports have been hyperbolic. Stem cell businesses use both these papers when marketing directly to consumers. They refer to these studies, and they also attach themselves to the bubbly media coverage.

MP: Consumers need to know that these products can be dangerous.

LT: Yes. The danger comes in several forms. Part of it is that these are financial scams lifting money off people who are worried and anxious. But, also, giving someone a product that hasnt been carefully tested in well-designed clinical trials raises a lot of concerns. Some businesses have released contaminated stem cell products into the marketplace. People end up getting infections and having to be hospitalized. It can be a very serious thing. Theres also the possibility that the wrong type of cell goes to the wrong part of the body and causes harm. When a company claims, for example, that a stem cell product will regenerate lung tissue and be an immune booster, one thing I would worry about is pulmonary embolisms. If someone is being given something that hasnt been thoroughly tested, its hard to know what would go wrong, but its easy to know something could go wrong.

FMI: Youll find the article on Cell Stem Cells website.

The rest is here:
Unproven stem cell products are being peddled as COVID-19 'therapies,' U of M researcher reports - MinnPost

Clinical Trial Shows Topical Stem Cell Treatment Leads to Hair Regrowth in Common Type of Baldness – Technology Networks

The results of a new clinical trial published in the journal STEM CELLS Translational Medicine demonstrate how a topical solution made up of stem cells leads to the regrowth of hair for people with a common type of baldness.1

Unfortunately, there are only a few FDA-approved medications to treat hair loss, and these carry a myriad of associated side effects including a negative impact on sexual functioning. There is therefore a pertinent need to develop anti-hair loss treatments that lack such side effects.

Emerging research has demonstrated the potential application of stem cells, particularly adipose tissue-derived stem cells (ADSCs), in this space. ADSCs are a type of mesenchymal stem cell that secrete several growth hormones that facilitate cell development and proliferation.

As previous research has demonstrated that growth factors such as hepatocyte growth factor, vascular endothelial growth factor, insulin-like growth factor and platelet-derived growth factor increase the size of hair follicles during hair development, scientists have explored whether ADSCs can promote hair growth in men and women with alopecia.2,3 The results of such research have been positive, however, a randomized, placebo-controlled trial of such a therapeutic approach in AGA did not exist until now.

"Recent studies have shown that ADSCs promote hair growth in both men and women with alopecia. However, no randomized, placebo-controlled trial in humans has explored the effects and safety of adipose-derived stem cell constituent extract (ADSC-CE) in AGA," says Sang Yeoup Lee, M.D., Ph.D., of the Family Medicine Clinic and Research Institute of Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital. "We aimed to assess the efficacy and tolerability of ADSC-CE in middle-aged patients with AGA in our study, hypothesizing that it is an effective and safe treatment agent."

Participants were instructed to apply 2mL of solution to the area in which they experienced hair loss, twice every day for a total of 16 weeks, massaging the solution into their scalp using their fingers. Each subjected visited the research center four times in total throughout the study, and were requested to keep a diary to record when they were using the solution.

To measure whether the solution was significantly impacting hair growth, the scientists measured changes in total hair number and hair thickness as confirmed by close contract photographs using a standardized technique. This was the primary efficacy variable. Photographs were taken at baseline, eight weeks and 16 weeks after using the product. At baseline, participants received a dot tattoo over their scalp to ensure that the photographs were taken at the same spot at each follow up. The secondary efficacy variables of the study included analysis of global photographs of the participants' scalps by an investigator, and self-evaluation of hair growth by the participants.

Whilst these results are promising, the authors note several limitations to the study. When assessing the secondary efficacy outcomes, the researchers found that the improvement score provided by the investigator was higher in the intervention group than the control, but this was not a significant increase. Additionally, the evaluation provided by the subject was lower in the intervention group. The scientists suggest that a contributing factor here could be the study duration, positing the idea that the length of time in which the participants were involved in the trial may not have been sufficient for them to notice a visual improvement. Furthermore, the self-report assessment could have been limited in validity as subjects may have been impacted by their own expectations towards the intervention. A solution to consider going forward could be to ask participants about their expectations regarding the magnitude of improvement at baseline.

Lee adds, "Our findings suggest that the application of the ADSC-CE topical solution has enormous potential as an alternative therapeutic strategy for hair regrowth in patients with AGA, by increasing both hair density and thickness while maintaining adequate treatment safety. The next step should be to conduct similar studies with large and diverse populations in order to confirm the beneficial effects of ADSC-CE on hair growth and elucidate the mechanisms responsible for the action of ADSC-CE in humans."

"For the millions of people who suffer from male-pattern baldness, this small clinical trial offers hope of a future treatment for hair regrowth," says Anthony Atala, M.D., Editor-in-Chief ofSTEM CELLS Translational Medicineand director of the Wake Forest Institute for Regenerative Medicine. "The topical solution created from proteins secreted by stem cells found in fat tissue proves to be both safe and effective. We look forward to further findings that support this work."

References:

1. Tak, Lee, Cho and Kim. (2020). A randomized, doubleblind, vehiclecontrolled clinical study of hair regeneration using adiposederived stem cell constituent extract in androgenetic alopecia. Stem Cells Translational Medicine. DOI: https://doi.org/10.1002/sctm.19-0410.

2. Ramdasi S, Tiwari SK. (2016). Growth factors and cytokines secreted in conditioned media by mesenchymal stem cells-promising possible therapeutic approach for hair regeneration. J Stem Cells. https://www.ncbi.nlm.nih.gov/pubmed/28296872.

3. Lee et al. (2001). Hepatocyte growth factor (HGF) activator expressed in hair follicles is involved in in vitro HGF-dependent hair follicle elongation. J Dermatol Sci. 25:156-163.

See the original post here:
Clinical Trial Shows Topical Stem Cell Treatment Leads to Hair Regrowth in Common Type of Baldness - Technology Networks

Tyson, Ronaldo, and more sports stars who use stem cell treatment costing up to 15,000 to speed up healing – The Sun

THE world's top sports stars are preferring to use stem cell treatment, instead of undergoing major surgery that could leave them out for months.

Cristiano Ronaldo, Rafael Nadal, and most recently Mike Tyson have all tried the therapy, which can cost anywhere from 4,000 to 15,000, when they've suffered injury.

Ailments that can be treated, include tendon inflammation, muscle strain, arthritis, degenerative disc disease, and even bone fractures.

And sportsman who have undergone stem cell therapy are benefitting from improved results, as well as a faster recovery time.

Collected from the blood from a newborn babys umbilical cord, the bone marrow or from body fat, stem cells are injected into an athletes' affected area.

They get to work by replenishing damaged cells from an injury or through wear and tear.

Stem cells also help reduce pain and inflammation, increase blood flow, and promote soft-tissue growth.

It helps the body to heal naturally, and means sports stars can potentially avoid going under the surgeon's knife.

When you're a top sports star, if you get injured the first thing you want to do is get back into the thick of action as quick as possible.

Unfortunately, many injuries can take a long time to heal, and will never allow the sportsman in question to return to the same level he/she was at before the injury.

That's where stem cell treatment is a game-changer.

Forget surgery, steroid injections, and lengthy physiotherapy, which don't always repair the issue at hand.

Stem cell treatments offer an alternative, albeit at a price, to have a non-surgical therapy that's non-evasive and, more importantly, heals the problem fast cutting out the need of rehabilitation.

Better still, some patients have reported that the therapy has not only reversed existing damage, but has strengthened cells against further damage.

Juventus star Ronaldo and Spanish tennis hero Nadal are all fans of stem cell treatment.

Back in 2016, when the Portuguese forward was playing for Real Madrid, he suffered a hamstring tear that threatened to keep him out of action of an important Champions League game against Manchester City.

Although he missed the first leg, he was back for the second - less than three weeks after suffering the problem.

That same year, Ronaldo tore a collateral ligament in his knee during Portugals Euro 2016 final against France.

Again, he turned to stem cell treatment and was back in training with Los Blancos just a month after his knee complaint.

Nadal's chronic knee problems forced him to take seven months off from tennis in 2013.

But stem cell treatment allowed the cartilage to repair. In the seven years since he's won six Grand Slams, there's been no setbacks from his troublesome knee and he appears as mobile as ever.

The Spaniard also cured a long-standing back problem with the therapy.

The former heavyweight champion, who is considering making a comeback, is the latest name to have tried stem cell treatment.

'DEEP SADNESS'Olympic legend Sir Bradley Wiggins and his wife announce they are separating

FIGHT FOR THE AGESHow heavyweights Tyson and Briggs compare with combined age of 101

YOUNG AT HEARTEx-football stars who scored with sexy younger Wags after hanging up boots

Revealed

PARD UP FOR CASHLampard snubbed chance to become Ipswich boss... as they had no money

Exclusive

ACE NICKEDChelsea's Hudson-Odoi arrested after 4am row with model while breaking lockdown

'APPALLED AT MYSELF'Lineker & Hancock apologise to Chadwick after cruel jokes on his looks

'AT RISK'Deeney says he's refused to return to Watford training over coronavirus fears

LAID BAREStunning Russian athlete offered 160k-a-month to become high-class escort

It is not known what Tyson, 53, was suffering from - but he was happy to reveal all in an Instagram chat with basketball legend Shaquille O'Neal.

Iron Mike said: "You know what I had done? I had stem-cell research therapy.

"I feel like a different person but I can't comprehend why I feel this way. It's really wild what scientists can do."

Here is the original post:
Tyson, Ronaldo, and more sports stars who use stem cell treatment costing up to 15,000 to speed up healing - The Sun

Global Stem Cell Partnering Deals Collection (2010-2020): Access to Headline, Upfront, Milestone and Royalty Data – PRNewswire

DUBLIN, May 18, 2020 /PRNewswire/ -- The "Global Stem Cell Partnering Terms and Agreements 2010-2020" report has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Stem Cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Stem Cell agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Stem Cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Stem Cell partnering deals.

The report presents financial deal term values for Stem Cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Stem Cell partnering field; both the leading deal values and most active Stem Cell dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 600 online deal records of actual Stem Cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Stem Cell dealmaking.

A comprehensive series of appendices is provided organized by Stem Cell partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Stem Cell partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Stem Cell technologies and products.

Analyzing actual contract agreements allows assessment of the following:

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/9pqrta

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Here is the original post:
Global Stem Cell Partnering Deals Collection (2010-2020): Access to Headline, Upfront, Milestone and Royalty Data - PRNewswire

COVID-19 Impact on Human Embryonic Stem Cell Market 2020 Regional Outlook, Latest Trend, Share Analysis, Growth, Application and Forecast to 2027 -…

The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries including Life science Industry, and many more. Trade barriers are further restraining the demand- supply outlook. As government of different regions have already announced total lockdown and temporarily shutdown of industries, the overall production process being adversely affected; thus, hinder the overall Human Embryonic Stem Cell market globally. This report on Human Embryonic Stem Cell market provides the analysis on impact on Covid-19 on various business segments and country markets. The report also showcase market trends and forecast to 2027, factoring the impact of Covid -19 Situation.

The human embryonic stem cells are obtained from the undifferentiated inner mass cell of the human embryo and human fetal tissue. The human embryonic stem cell can replicate indefinitely and produce non-regenerative tissue such as myocardial and neural cells. This potential of human embryonic stem cell allows them to provide an unlimited amount of tissue for transplantation therapies to treat a wide range of degenerative diseases. Hence, human embryonic stem cells are used in the treatment of various diseases such as Alzheimers disease, cancer, blood and genetic disorders related to the immune system and others.

Get the inside scope of the Sample report @https://www.theinsightpartners.com/sample/TIPRE00005165/

MARKET DYNAMICSThe global human embryonic stem cell market is expected to grow in upcoming years, factors driving the growth of market are rise in incidences of neurological disorders, increase in investment by government and other organization for research activities, awareness among people about stem cell therapeutic potency for disease treatment. On the other hand emerging stem cell banking services is expected to offer lucrative opportunities in growth of human embryonic stem cell market.

The report also includes the profiles of key human embryonic stem cell market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

Key Competitors In Market are

TOC pointsof Market Report:

Market size & shares

Market trends and dynamics

Market Drivers and Opportunities

Competitive landscape

Supply and demand

Technological inventions in industry

Marketing Channel Development Trend

Market Positioning

Pricing Strategy

Brand Strategy

Target Client

MARKET SCOPE

The Global Human Embryonic Stem Cell Market Analysis to 2027 is a specialized and in-depth study with a special focus on the global medical device market trend analysis. The report aims to provide an overview of human embryonic stem cell market with detailed market segmentation by product type, application, end users and geography. The global human embryonic stem cell market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading human embryonic stem cell market players and offers key trends and opportunities in the market.

Market segmentation:

Human Embryonic Stem Cell Market to 2027 Global Analysis and Forecasts By Product Type (Totipotent Stem Cell, Pluripotent Stem Cell, Unipotent stem Cell); Application (Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, Toxicology Testing); End User (Therapeutics Companies, Cell & Tissue Banks, Tools & Reagents Companies, Others) and Geography

By Geography North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. And 13 countries globally along with current trend and opportunities prevailing in the region.

The target audience for the report on the market

Manufactures

Market analysts

Senior executives

Business development managers

Technologists

R&D staff

Distributors

Investors

Governments

Equity research firms

Consultants

Click to buy full report with all description:-https://www.theinsightpartners.com/buy/TIPRE00005165/

About Us:

The Insight Partnersis a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email:[emailprotected]

Read the rest here:
COVID-19 Impact on Human Embryonic Stem Cell Market 2020 Regional Outlook, Latest Trend, Share Analysis, Growth, Application and Forecast to 2027 -...

Critical window for re-infection with HIV after stem cell transplantation – BioNews

18 May 2020

New research, in HIV positive patients being treated for blood cancer, has identified a critical time window after donor stem cell transplantation, during which the expanding donor cells are particularly vulnerable to being infected with HIV.

Patients with HIV who develop blood cancer may require treatment by allogeneic stem cell transplant, using bone marrow stem cells provided by a healthy donor. During a transplant, most of the patient's original immune cells are destroyed, and the immune system and blood cells are restored from the new donor stem cells.

'These results show a weak point that may explain why allogeneic stem cell transplants may not completely remove the virus from the body, despite a drastic reduction in the number of infected cells' saidsenior authorDr Julian Schulze zur Wiesch from the German Centre for Infection Research.

Stem cell transplantation in HIV positive patients has been the only medical intervention found to cure HIV (see BioNews 1039), however in nearly all cases HIV infection persists after transplantation.

In a new study it was discovered that immune cells generated from the donor stem cells are at risk of being infected with HIV during the first few weeks after transplantation.

In this study of 16 HIV positive participants with blood cancer, the researchers show that stem cell transplantation promotes reactivation of the virus within the patient's remaining original immune cells. This leads to some of the new immune cells becoming infected, thus 're-seeding' HIV within the host.

'Additional immunotherapy orgene therapy may be required to achieve ongoing, spontaneous control of HIV infection in people with HIV after allogeneic stem cell transplantation,' said Dr Schulze zur Wiesch.

This research was published in Science Translational Medicine.

Read the original:
Critical window for re-infection with HIV after stem cell transplantation - BioNews

COVID 19 PANDEMIC: Cancer Stem Cell Market Expert Guide to Boost the Industry in Market Share – Cole of Duty

The Cancer Stem Cell report provides independent information about the Cancer Stem Cell industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies profiles including business overview and recent development.

Cancer Stem Cell MarketLatest Research Report 2020:

Download Premium Sample Copy Of This Report: Download FREE Sample PDF!

In this report, our team offers a thorough investigation of Cancer Stem Cell Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth.

Scope of Cancer Stem Cell Market: Products in the Cancer Stem Cell classification furnish clients with assets to get ready for tests, tests, and evaluations.

Major Company Profiles Covered in This Report

Thermo Fisher Scientific, Inc.,AbbVie, Inc.,Merck KGaA,Bionomics,LONZA,Stemline Therapeutics, Inc,Miltenyi Biotec,PromoCell GmbH,MacroGenics, Inc.,ONCOMED PHARMACEUTICALS INC,Irvine Scientific,STEMCELL Technologies Inc,Sino Biological Inc,BIOTIME, INC.

Cancer Stem Cell Market Report Covers the Following Segments:

Product Type: Treatment Type,o Autologous Stem Cell Transplants,o Allogeneic Stem Cell Transplants,o Syngeneic Stem Cell Transplants,o Bone Marrow Stem Cell Transplants,Disease Type,o Breast Cancer,o Blood Cancer,o Lung Cancer,o Brain Cancer,o Colorectal Cancer,o Pancreatic Cancer,o Bladder Cancer,o Liver Cancer,o Others

North America

Europe

Asia-Pacific

South America

Center East and Africa

United States, Canada and Mexico

Germany, France, UK, Russia and Italy

China, Japan, Korea, India and Southeast Asia

Brazil, Argentina, Colombia

Saudi Arabia, UAE, Egypt, Nigeria and South Africa

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Cancer Stem Cell Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Cancer Stem Cell Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Cancer Stem Cell Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Cancer Stem Cell Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Cancer Stem Cell Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Cancer Stem Cell Market.

Market Forecast:Here, the report offers a complete forecast of the global Cancer Stem Cell Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Report:

https://www.marketwatch.com/press-release/medical-ceramics-market-us-industry-trends-share-size-growth-analysis-opportunity-and-forecast-2020-2025-2020-04-14

http://www.marketwatch.com/press-release/europe-medical-implants-market-size-industry-analysis-report-regional-outlook-application-development-trends-competitive-market-share-forecast-20202025-2020-04-15

http://www.marketwatch.com/press-release/us-electronic-medical-record-systems-market-2020-outlook-growth-top-companies-regions-applications-analysis-trends-and-opportunity-assessment-in-2025-2020-04-15

https://www.marketwatch.com/press-release/us-polio-vaccines-market-2020-share-business-strategies-product-sales-and-growth-rate-opportunity-assessment-to-2025-2020-04-15

Continued here:
COVID 19 PANDEMIC: Cancer Stem Cell Market Expert Guide to Boost the Industry in Market Share - Cole of Duty

Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market Development, Trends, Key Driven Factors, Segmentation And Forecast to 2020-2026 -…

Hospitals

The report is a compilation of different studies, including regional analysis where leading regional Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies markets are comprehensive studied by market experts. Both developed and developing regions and countries are covered in the report for a 360-degree geographic analysis of the Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies market. The regional analysis section helps readers to become familiar with the growth patterns of important regional Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies markets. It also provides information on lucrative opportunities available in key regional Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies markets.

Ask For Discounts, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=174132&utm_source=COD&utm_medium=888

Table of Content

1 Introduction of Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market, By Deployment Model

5.1 Overview

6 Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market, By Solution

6.1 Overview

7 Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market, By Vertical

7.1 Overview

8 Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report

@ https://www.marketresearchintellect.com/need-customization/?rid=174132&utm_source=COD&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market Size, Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market Trends, Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market Growth, Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market Forecast, Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Link:
Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market Development, Trends, Key Driven Factors, Segmentation And Forecast to 2020-2026 -...

How Coronavirus is Impacting Cell Isolation Technology Market Growth Opportunity and Industry Revenue Analysis by Major Players, 2019-2026 3w Market…

The research study presented in this report offers complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the Global Cell Isolation Technology Market. The research study has been prepared with the use of in-depth qualitative and quantitative analyses of the global Cell Isolation Technology market. We have also provided absolute dollar opportunity and other types of market analysis on the global Cell Isolation Technology market.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Cell Isolation Technology market. All findings and data on the global Cell Isolation Technology market provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global Cell Isolation Technology market available in different regions and countries.

The report on the Cell Isolation Technology market provides a birds eye view of the current proceeding within the Cell Isolation Technology market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Cell Isolation Technology market and offers a clear assessment of the projected market fluctuations during the forecast period.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2657647&source=atm

The authors of the report have segmented the global Cell Isolation Technology market as per product, application, and region. Segments of the global Cell Isolation Technology market are analyzed on the basis of market share, production, consumption, revenue, CAGR, market size, and more factors. The analysts have profiled leading players of the global Cell Isolation Technology market, keeping in view their recent developments, market share, sales, revenue, areas covered, product portfolios, and other aspects.

The key players covered in this studyThermo Fisher Scientific, Inc.MerckBD BiosciencesBeckman Coulter, Inc.Terumo BCTGE HealthcareStemcell TechnologiesBio-Rad Laboratories, Inc.

Market segment by Technology, the product can be split intoCentrifugationFlow CytometryCell ElectrophoresisMarket segment by Application, split intoStem cell researchCancer researchTissue regenerationIn-vitro diagnosticsOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Cell Isolation Technology status, future forecast, growth opportunity, key market and key players.To present the Cell Isolation Technology development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by technology, market and key regions.

In this study, the years considered to estimate the market size of Cell Isolation Technology are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, technology and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2657647&source=atm

Cell Isolation Technology Market Size and Forecast

In terms of region, this research report covers almost all the major regions across the globe such as North America, Europe, South America, the Middle East, and Africa and the Asia Pacific. Europe and North America regions are anticipated to show an upward growth in the years to come. While Cell Isolation Technology Market in Asia Pacific regions is likely to show remarkable growth during the forecasted period. Cutting edge technology and innovations are the most important traits of the North America region and thats the reason most of the time the US dominates the global markets. Cell Isolation Technology Market in South, America region is also expected to grow in near future.

The Cell Isolation Technology Market report highlights is as follows:

This Cell Isolation Technology market report provides complete market overview which offers the competitive market scenario among major players of the industry, proper understanding of the growth opportunities, and advanced business strategies used by the market in the current and forecast period.

This Cell Isolation Technology Market report will help a business or an individual to take appropriate business decision and sound actions to be taken after understanding the growth restraining factors, market risks, market situation, market estimation of the competitors.

The expected Cell Isolation Technology Market growth and development status can be understood in a better way through this five-year forecast information presented in this report

This Cell Isolation Technology Market research report aids as a broad guideline which provides in-depth insights and detailed analysis of several trade verticals.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2657647&licType=S&source=atm

Read this article:
How Coronavirus is Impacting Cell Isolation Technology Market Growth Opportunity and Industry Revenue Analysis by Major Players, 2019-2026 3w Market...

‘No silver bullet’: Investors cautioned as market surges on vaccine hopes – Sydney Morning Herald

Health stocks are still ahead by more than 6 per cent since the start of the year, compared to the broader S&P/ASX200, which has slumped 18 per cent since January.

Local medtechs across the board have been pivoting their research to coronavirus treatments and cures, with some seeing big share price gains. Stem cell company Mesoblast is up 85 per cent since January on news of its coronavirus treatment trials.

Despite this, analysts warn investors that there are hurdles in the way for companies hoping to achieve share price gains from treatment research.

My sense is that theres quite an onus on these companies to take a humanitarian as opposed to commercial point of view.

Morningstar equities analyst Nicolette Quinn said there was a myriad of local companies looking to come up with coronavirus trials, but many of these businesses had never fully commercialised a product before.

Ms Quinn ceased coverage of Mesoblast earlier this year but observed that while the company had taken its first steps into research, "they dont yet have a track record of launching a product".

The other challenge for companies looking to develop virus treatments is that they may not see strong profits from these if they do come to market, Ms Quinn said.

"My sense is that theres quite an onus on these companies to take a humanitarian as opposed to commercial point of view," she said.

Any company that came up with a treatment or vaccine would likely have to work with others to commercialise it and avoid being seen as profiteering, she said. "It will be, 'how profitable can they make it'?"

The share price of Australia's largest business by market value, CSL has climbed 12 per cent since January. Over the past two months the company has unveiled a range of coronavirus research initiatives, including working with the University of Queensland on a vaccine candidate and developing plasma-based therapies to help those with severe respiratoryissues.

Loading

Ms Quinn said while she was watching testing and treatment developments closely, she was not viewing CSL's virus research as important to the company's overall operations or a "major contributor to their bottom line".

Mr Low agreed that news about treatments were not affecting how he viewed local stocks. Many treatment projects fail after the first round of clinical trials, meaning for every good piece of news about progress, the market was likely to face setbacks, he said.

"There will also be days with bad news on this front if only around 10 per cent of trials succeed. For the moment, this [news of vaccine developments] has little bearing on the Australian health companies I follow," he said.

Emma is the small business reporter for The Age and Sydney Morning Herald based in Melbourne.

View post:
'No silver bullet': Investors cautioned as market surges on vaccine hopes - Sydney Morning Herald